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Accepted 19 October 2017Background: Remote ischaemic preconditioning (RIPC) is a cardioprotective intervention invoking intermittent
periods of ischaemia in a tissue or organ remote from the heart. The mechanisms of this effect are incompletely
understood. We hypothesised that RIPC might enhance coronary vasodilatation by an endothelium-dependent
mechanism.
Methods:We performed a prospective, randomised, sham-controlled, blinded clinical trial. Patients with stable
coronary artery disease (CAD) undergoing elective invasive management were prospectively enrolled,
and randomised to RIPC or sham (1:1) prior to angiography. Endothelial-dependent vasodilator function
was assessed in a non-target coronary artery with intracoronary infusion of incremental acetylcholine doses
(10−6, 10−5, 10−4 mol/l). Venous blood was sampled pre- and post-RIPC or sham, and analysed for circulating
markers of endothelial function. Coronary luminal diameter was assessed by quantitative coronary angiography.
The primary outcomewas the between-group difference in themean percentage change in coronary luminal di-
ameter following the maximal acetylcholine dose (Clinicaltrials.gov identiﬁer: NCT02666235).
Results: 75 patients were enrolled. Following angiography, 60 patients (mean ± SD age 57.5 ± 8.5 years; 80%
male) were eligible and completed the protocol (n = 30 RIPC, n = 30 sham). The mean percentage change in
coronary luminal diameter was−13.3 ± 22.3% and−2.0 ± 17.2% in the sham and RIPC groups respectively
(difference 11.32%, 95%CI: 1.2– 21.4, p = 0.032). This remained signiﬁcant when age and sex were included as
covariates (difference 11.01%, 95%CI: 1.01– 21.0, p = 0.035). There were no between-group differences in
endothelial-independent vasodilation, ECG parameters or circulating markers of endothelial function.
Conclusions: RIPC attenuates the extent of vasoconstriction induced by intracoronary acetylcholine infusion. This
endothelium-dependent mechanism may contribute to the cardioprotective effects of RIPC.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Ischaemic conditioning describes the beneﬁcial effects of repeated
cycles of ischaemia and reperfusion resulting in cardioprotection
against ischaemia-reperfusion injury [1–6]. This cardioprotective
strategy may be applied either directly to the heart or remotely, and
before or during ischaemia-reperfusion injury [7]. Remote ischaemic
preconditioning (RIPC) has been investigated in several ischaemia-
reperfusion injury clinical settings, including patients with stable coro-
nary artery disease (CAD) undergoing elective percutaneous coronary
intervention (PCI) and surgical revascularisation [8–15]. RIPC is associ-
ated with a reduction in infarct size in patients following an acute myo-
cardial infarction (MI) and after elective PCI in patients with stable CAD
[8,16,17]. Themechanisms bywhich the cardioprotective effects of RIPCe under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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comes in patients with acute ST-segment elevation myocardial infarc-
tion (STEMI) are currently being assessed in two large phase 3 clinical
trials in Europe (CONDI-2 NCT01857414 and ERIC NCT02342522).
Three components of the RIPC stimulus may be deﬁned: signal
generation from the tissue or organ remote from the heart, transmission
of the cardioprotective signal to the heart, and the mechanism of the
cardiac response [19]. The molecular mechanisms and signal transduc-
tion of the conditioning phenomena in the heart have been described
as involving extracellular trigger molecules, intracellular protein kinase
activation and the mitochondria as the end-effector [20]. The signal
transduction from the distant organ/tissue to the heart is incompletely
understood, but likely involves both neural and hormonal pathways
[21–24].
Since coronary artery function has pivotal importance for regulating
myocardial perfusion, we hypothesised that RIPC would have favourable
effects on coronary artery endothelial dysfunction. Endothelial dysfunc-
tion is prevalent in patients with atherosclerotic CAD and associated
with adverse health outcomes [25–27]. Thismechanism could potentially
contribute to the cardioprotective effects of RIPC through enhanced
coronary artery blood ﬂow leading to improved myocardial perfusion
following ischaemia-reperfusion injury. Studies of RIPC have identiﬁed
endothelial-dependent responses that potentially implicate endothelial
cell activation in mediating enhanced coronary blood ﬂow and
cardioprotective effects [28–31]. Conversely,we are not aware of exper-
imental evidence for an effect of RIPC on endothelial-independent
vascular function.
Our ﬁrst aim was to determine whether RIPC might affect coronary
artery function in vivo in patients with stable CAD. Should this be the
case, we next aimed to determine the contribution of endothelium-
dependent and -independent function on the observed responses. Our
second aim was to assess whether circulating molecules reﬂecting en-
dothelial cell vasodilatory and ﬁbrinolytic function might be associated
with a RIPC-mediated effect on coronary artery function. Thirdly, since a
neural hypothesis implicates activation of the autonomic nervous
system via one or more pathways [32–34], we aimed to assess cardiac
conduction using the surface electrocardiogram (ECG) [35].
2. Methods
2.1. Trial design
We performed a prospective, randomised, sham-controlled, blinded (physician,
researcher) clinical trial.2.2. Study population
Patients undergoing elective invasive coronary angiography for investigation of stable
CADwere enrolled and providedwritten informed consent. The studywas approved by the
National Research Ethics Service (reference 10/S0704/52). The ClinicalTrials.gov identiﬁer
is NCT02666235. Patients were eligible if, following initial coronary angiography, there
was a main epicardial coronary artery suitable for coronary reactivity testing (either an
angiographically normal coronary artery, or an artery with minimal plaque burden and
without an epicardial diameter stenosis ≥40%). Exclusion criteria were MI b2 weeks,
previous coronary artery bypass grafting, second or third degree atrioventricular block,
and inability to provide informed consent.2.3. Setting
The study took place between July 2011 and March 2016 in a regional cardiac centre.
Potentially eligible participants were identiﬁed by screening clinically-indicated referrals
for invasive coronary angiography.2.4. Informed consent
Eligible patients were sent a Patient Information Sheet (PIS) before attending hospital
for the clinically-indicated coronary angiogram. The PIS had been approved by the local
ethics committee and written informed consent was obtained on the ward before the
procedure.2.5. Randomisation, implementation and blinding
Randomisation took place immediately after obtaining verbal consent using a
web-based computer tool with a concealed random allocation sequence provided by the
independent clinical trials unit and implemented by the researcher (D.C.). Randomisation
was on a 1:1 basis between RIPC or sham immediately prior to the invasive procedure. The
study was conducted according to CONSORT guidelines for clinical trials.2.6. Intervention
2.6.1. Remote ischaemic preconditioning
RIPC was performed according to a standard protocol involving intermittent inﬂation
of an arm sphygmomanometer cuff for 5 min periods at 200 mm Hg, separated by a
5-minute rest interval, and repeated successively on 4 occasions [8].2.6.2. Sham procedure
The sham procedure involved cuff placement alone without inﬂation.
Following theRIPC or shamprocedure, patients underwent angiography and coronary
reactivity testing within 1 h.2.7. Primary and secondary endpoints
The protocol for end-point acquisition and assessment is illustrated in Fig. 1.2.8. Assessment of physiological responses of the coronary artery and microcirculation
All vasodilator therapy apart from sublingual glyceryl trinitrate was withheld for 24 h
prior to coronary reactivity testing. Coronary angiograms were acquired using cardiac
catheter laboratory X-ray (Innova®, GE Healthcare; Chicago, Illinois) and information
technology equipment (Centricity®, GE Healthcare).
Reactivity testing of the coronary circulation, including the epicardial artery and its
microvascular branches, included assessments of endothelial-dependent vasodilation
following intracoronary infusion of graded doses of acetylcholine, and then assessment of
endothelial-independent vasodilation following intracoronary administration of glyceryl
trinitrate.
Endothelial function testingwas performed using a standardised protocol by an oper-
ator blinded to the group allocation [36]. A 3 French infusion catheter (Cook Medical;
Bloomington, Indiana) was placed in the proximal-to-mid segment of the epicardial cor-
onary artery. A control intracoronary infusion of a 0.9% saline (2 ml over 2 min)
was followed by intracoronary acetylcholine in incremental concentrations (10−6, 10−5,
10−4 mol/l). The infusion rate of acetylcholine was 2 ml/min giving approximate doses
of 0.364, 3.64, and 36.4 μg, respectively.
Following each intracoronary infusion, an assessment of patient symptoms, 12 lead
ECG, and angiography using identical imaging projections (Innova®, GE Healthcare)
and information technology equipment (Centricity®, GE Healthcare) were performed.
Acetylcholine infusion was discontinued if: i) second or third degree atrioventricular
block occurred; ii) there was angiographic evidence of severe epicardial vasospasm
(reduction in the epicardial diameter ≥75%); iii) therewas evidence of severemicrovascular
spasm(anginaand ST-segment deviation occurring in theabsence of epicardial coronary di-
ameter change ≥75%) [37]. If these criteriawere not present, we administered thenext dose
of acetylcholine. Following a second wash-out infusion of 0.9% saline for a period of 2 min,
endothelial-independent vasodilation was tested with an intracoronary bolus of glyceryl
trinitrate (400 μg).2.9. Invasive coronary angiography and analysis
Quantitative coronary angiography (QCA)was performed by three experienced cardi-
ologists (P.C., A.B., C.B.) in the Glasgow Angiography Core Laboratory, using proprietary
automated edge-detection software (Medis QAngio XA, Leiden, Netherlands). The angio-
graphic images were calibrated to the coronary guide catheter size. The end-diastolic
angiographic image demonstrating the best luminal contrast opaciﬁcation was chosen
for analysis. The coronary segment distal to the infusion catheter or the coronary segment
demonstrating the most marked diameter change in the main epicardial vessel was
analysed to determine the mean coronary artery luminal diameter for the selected
segment. Analysts were blinded to the group assignment.2.10. Mechanistic evaluation of circulating biomarkers of endothelial function
Venous bloodwas obtained from the contralateral arm pre- and thenwithin 1 h post-
RIPC or sham procedure. Venous blood was analysed for circulating molecules associated
with endothelial vasodilator function (myeloperoxidase (MPO), interleukin-6 (IL-6), von
Willebrand factor (vWF), asymmetric dimethylarginine (ADMA)) and endothelial ﬁbrino-
lytic function (tissue plasminogen activator (t-PA)). Laboratory methods are described in
the online-only supplement. Laboratory technicians were blinded to the group allocation.
Fig. 1. Illustration of the RIC-COR study protocol. RIPC = remote ischaemic preconditioning.
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2.11.1. Acquisition
We acquired 12-lead ECGs (Centricity®, GE Healthcare) before and after each
2-minute intracoronary infusion of acetylcholine to assess for changes in cardiac conduction
linked to autonomic nervous system activation.2.11.2. Analysis
ECGswere analysed in theGlasgowECGCore Laboratory by a blinded analyst (P.McC.)
for PR duration, QRS duration, corrected QT interval (QTc, deﬁned as the QT interval
corrected for heart rate using Bazett's formula), presence of atrioventricular block and
ST-segment deviation.2.12. Statistical analyses
2.12.1. Sample size calculation
Our pilot data found the standard deviation of the percentage change in mean lumen
diameter for the maximum dose of acetylcholine administered compared to control to be
14.6%. Based on a two-sample t-test, 25 patients per group were required to have 80%
power at a 5% signiﬁcance level to detect a mean between group difference of 12%. A net
difference of 12% is consistent with previously published effective treatments which
improve coronary artery function.2.12.2. Primary outcome
The pre-deﬁned primary outcome was the mean percentage change in coronary ar-
tery luminal diameter frombaseline to themaximumadministered acetylcholine infusion,
using an analysis of variance (ANOVA)model. An analysis of covariance (ANCOVA)model
was used to assess for the inﬂuence of age and sex. Data are presented as mean (SD) or n
(%) where appropriate. Fisher's exact test was used to compare the between group differ-
ence in the coronary vessel undergoing interrogation. Statistical analyses were performed
by an independent biostatistician using R version 3.1.2 (R.Y. based in the Glasgow Clinical
Trials Unit). All p values are two-sided and a p value b0.05 was considered statistically
signiﬁcant.2.12.3. Secondary outcomes
Pre-speciﬁed secondary outcomes were intended to provide information on
mechanisms of the physiological responses.
Secondary outcomes deﬁned by quantitative coronary angiography analysis:
1. Mean percentage change in coronary luminal diameter from baseline following
intracoronary glyceryl trinitrate (400 μg).
2. Coronary endothelial dysfunction (deﬁned as a decrease in luminal diameter of N20%
following intracoronary acetylcholine).
3. Epicardial coronary artery spasm (deﬁned as a reduction in coronary luminal diameter
N90% following intracoronary acetylcholine [38].
Secondary outcomes deﬁned by electrocardiography:
4. Microvascular spasm(deﬁned as the occurrence of anginawith ischaemic ST-segment
ECG changes in the absence of epicardial coronary vasospasm (≤90% coronary luminal
diameter reduction) [37,39].
5. Presence and extent of ST-segment deviation (ST-segment elevation or depression).
6. Occurrence of atrioventricular block.
Secondary outcomes determined by immunoassays:
7. Circulating molecules reﬂecting endothelial function from baseline to up to 2 h.
3. Results
3.1. Study population
Seventy-ﬁve patients provided written informed consent and were
randomised to RIPC or sham procedure (Table 1 and Fig. 2). Following
diagnostic coronary angiography, 60 patients completed the study pro-
tocol (RIPC group n = 30, sham group n = 30). RIPC and sham proce-
dures were well-tolerated (100% compliance), and no serious adverse
events (SAEs) occurred. The left anterior descending, circumﬂex and
right coronary arteries were evaluated in 13 (22%), 20 (33%), and 27
Table 1
Baseline clinical characteristics.
Variable Sham
(n = 30)
RIPC
(n = 30)
p-value
Age, years 57.8 (9.6) 57.2 (7.4) 0.79
Male sex 25 (83.3%) 23 (76.7%) 0.75
BMI, kg/m2 29.5 (5.0) 29.4 (3.9) 0.91
Blood pressure, mm Hg
- Systolic 131.8 (18.5) 137.1 (21.8) 0.31
- Diastolic 70.4 (9.2) 75.9 (11.4) 0.04
Medical history
Hypercholesterolaemia 16 (53.3%) 22 (73.3%) 0.18
Diabetes Mellitus 5 (16.7%) 6 (20.0%) 0.99
Current smoker 6 (20.0%) 8 (26.7%) 0.76
Hypertension 13 (43.3%) 21 (70.0%) 0.06
Family history of CAD 21 (70.0%) 19 (63.3%) 0.78
Prior myocardial infarction 8 (26.7%) 7 (23.3%) 0.99
Prior PCI 5 (16.7%) 4 (13.3%) 0.99
Cerebrovascular Disease 0 (0.0%) 1 (3.3%) 0.99
Renal dysfunction (eGFR b60 ml/min) 2 (6.7%) 2 (6.7%) 0.99
Baseline drug therapy
- Aspirin 28 (93.3%) 25 (83.3%) 0.42
- Clopidogrel 11 (36.7%) 9 (30.0%) 0.78
- Ticagrelor 2 (6.7%) 2 (6.7%) 0.99
- ACEi 16 (53.3%) 14 (46.7%) 0.80
- ARB 0 (0.0%) 3 (10.0%) 0.24
- Statin 27 (90.0%) 27 (90.0%) 0.99
- β-blocker 29 (96.7%) 22 (73.3%) 0.03
- Calcium-channel blocker 7 (23.3%) 12 (40.0%) 0.27
- Oral nitrate 10 (33.3%) 8 (26.7%) 0.78
- Nicorandil 3 (10.0%) 5 (16.7%) 0.71
Baseline mean coronary artery luminal
diameter, mm
2.40 (0.53) 2.55 (0.54) 0.28
Data are presented as Mean (SD) or n (%) where appropriate. CAD= coronary artery dis-
ease, PCI = percutaneous coronary intervention, BMI = body mass index, ACEi =
angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, eGFR =
estimated glomerular ﬁltration rate.
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groups (p= 0.79). In 15 patients, the coronary reactivity testing proto-
col was not performed (RIPC group (n=7), sham group (n=8) for theFig. 2. CONSORT (Consolidated Standards of Reporting Trials)following reasons: no suitable vessel for coronary reactivity testing
(n = 7), complications relating to diagnostic coronary angiography
(n = 4), inability to maintain a stable intracoronary infusion catheter
position (n=3), coronary artery dissection (n=1). Of the remaining 60
patients, 30 (100%) in the RIPC group and 27 (90%) in the sham group
completed the coronary reactivity testing protocol. Three patients, all in
the sham group, met the pre-speciﬁed criteria to discontinue the acetyl-
choline infusion before completing the protocol, for the following
reasons: severe epicardial spasm (n=2) and second degree atrioventric-
ular block (n = 1).
3.2. Primary outcome: coronary lumen diameter following intracoronary
infusion of acetylcholine
The mean percentage change in coronary luminal diameter from
baseline to the maximum administered acetylcholine dose was−13.3
(22.3) and −2.0 (17.2) % in the sham and RIPC groups, respectively
(Table 2). There was a lower mean percentage reduction in coronary
luminal diameter in the RIPC compared to shamgroup (meandifference
11.32%, 95% CI: 1.2 to 21.4, p = 0.032). This difference remained signif-
icant when accounting for the inﬂuence of age and sex by including
these characteristics as covariates in an ANCOVA model (mean differ-
ence 11.01%, 95% CI: 1.01 to 21.0, p = 0.035).
3.3. Secondary outcomes
3.3.1. Coronary reactivity testing secondary outcomes
There was no between group difference in endothelial-independent
vasodilation in the RIPC compared to sham group (mean coronary lumi-
nal percentage diameter change 1.2%, 95% CI: −3.4 to 5.8, p = 0.61)
(Table 2). There was no statistically signiﬁcant between group differ-
ence in the number of patients meeting the criteria for endothelial
dysfunction (4 (13.3%) vs. 8 patients (26.7%), p = 0.33), epicardial vaso-
spasm (0 (0.0%) vs. 1 patient (3.3%), p = 0.99), and microvascular
spasm (4 (13.3%) vs. 3 patients (10.3%), p = 1.00), in the RIPC compared
to sham group, respectively.ﬂow diagram. RIPC = remote ischaemic preconditioning.
Table 2
Primary and secondary outcomes.
Variable Sham (n = 30)
Mean (SD)
RIPC (n = 30)
Mean (SD)
Between group difference
in change from baseline
Mean (CI)
p-value
Coronary reactivity testing
Endothelial-dependent vasoreactivity testing (Mean coronary diameter at
maximum ACh dose administered, mm)
2.08 (0.72) 2.50 (0.66) 11.32% (1.24, 21.40) 0.032
Endothelial-independent vasoreactivity testing (Mean coronary diameter
following intracoronary GTN, mm)
2.59 (0.48) 2.78 (0.52) 1.18% (−3.38, 5.75) 0.61
Circulating cytokines implicated in endothelial function
MPO, ng/ml Pre 3.7 (5.1)
Post 3.4 (3.8)
Pre 3.8 (3.2)
Post 2.9 (2.3)
−0.5 (−2.15, 1.15) 0.55
IL-6, pg/ml Pre 3.5 (2.7)
Post 2.8 (1.4)
Pre 3.4 (2.1)
Post 3.0 (1.9)
0.32 (−0.71, 1.36) 0.54
tPA, ng/ml Pre 5.7 (1.7)
Post 5.4 (2.2)
Pre 6.0 (2.0)
Post 6.2 (2.6)
0.45 (−0.24, 1.14) 0.20
vWF, U/ml Pre 144.3 (24.8)
Post 138.3 (26.4)
Pre 137.7 (26.6)
Post 135.0 (32.0)
3.31 (−4.58, 11.19) 0.41
ADMA, μmol/l Pre 0.45 (0.08)
Post 0.43 (0.09)
Pre 0.44 (0.09)
Post 0.43 (0.09)
0.01 (−0.03, 0.05) 0.57
Electrocardiogram ﬁndings
PR duration, ms 9.6 (42.0) 0.4 (42.0) −9.2 (−33.73, 15.33) 0.47
QRS duration, ms −1.8 (9.4) −1.3 (15.1) 0.54 (−6.18, 7.26) 0.88
QTc duration, ms 4.7 (80.2) −26.6 (68.5) −31.32 (−78.53, 15.9) 0.20
R-R interval, ms −7.0 (75.2) 6.5 (61.3) 13.57 (−21.63, 48.77) 0.45
ACh = acetylcholine, GTN = glyceryl trinitrate, MPO =myeloperoxidase, IL-6 = interleukin-6, tPA = tissue plasminogen activator, vWF = von Willebrand factor.
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There were no between-group differences the ECG parameters
(change from baseline in PR duration, QRS duration, QTc duration, or
R-R interval; occurrence of atrioventricular block at the maximum
administered dose of acetylcholine; ST-segment deviation).
3.3.3. Circulating cytokines implicated in endothelial function
There were no differences in the circulating concentrations of
markers of endothelial function in the RIPC compared to sham group
(Table 2).
4. Discussion
We undertook amechanistic, randomised, sham-controlled, blinded
clinical trial of the effect of RIPC on endothelial function in the coronary
circulation of patients with stable CAD. We have shown that RIPC
performed immediately prior to invasive management results in a
lower reduction in mean percentage coronary artery luminal diameter,
consistent with enhanced coronary endothelial function. In other
words, RIPC attenuated the extent of coronary vasoconstriction induced
by intracoronary acetylcholine infusion. Secondly, RIPC did not result in
increased circulating concentrations of several circulating cytokines
that are implicated in endothelial vasodilator function (MPO, IL-6,
vWF, ADMA) or in a marker of endothelial ﬁbrinolytic function (t-PA).
Thirdly, RIPC did not have an effect on cardiac conduction or on
ST-segment deviation.
Our mechanistic results relating to RIPC and coronary endothelial
function are novel and clinically relevant. RIPC had a moderate but
tangible effect on coronary artery vasoconstriction (difference in mean
percentage reduction in coronary luminal diameter 11.32%) in non-
obstructed epicardial coronary arteries. Since the intervention was
applied immediately before invasive management, it is transferable
into clinical practice. Further, to minimise bias and enhance validity,
the study design involved random assignment of treatment allocation,
a sham procedure, researcher blinding, and independent statistical
analysis.
The study participants all had stable CAD, and coronary endothelial
dysfunction was prevalent. In normal coronary arteries, acetylcholine
results in vasodilatation due to endothelial release of nitric oxide andresultant smooth muscle relaxation. In arteries with endothelial dys-
function, the direct action of acetylcholine on muscarinic smooth mus-
cle receptors is unopposed and results in vasoconstriction [40]. In both
groups of patients, a reduction in coronary artery diameter occurred
with themaximumdose of acetylcholine administered, indicative of en-
dothelial dysfunction co-existent with the underlying atherosclerotic
CAD. However, the percentage change in mean coronary luminal diam-
eter was lower with RIPC compared to sham i.e. there was less vasocon-
striction with RIPC compared to the sham procedure.
Whether the cardioprotective mechanism induced by RIPC involves
enhanced coronary blood ﬂow is uncertain. Data from animal models
and healthy human volunteers suggest that resting coronary blood
ﬂow may be enhanced by RIPC [41,42]. Hoole et al. demonstrated that
RIPC does not reduce coronary microvascular resistance, as assessed
invasively using coronary thermodilution and Doppler ﬂow velocity
techniques, or enhance resting or hyperaemic coronary Doppler
ﬂow velocity [43]. In 54 patients with single and multi-vessel CAD
undergoing elective PCI, therewasno change in the index ofmicrocircu-
latory resistance (IMR) or Doppler-derived microvascular resistance
following both RIPC or cardiac ischaemic preconditioning [44,45]. Our
data indicate that RIPC alleviates vasoconstriction in atherosclerotic cor-
onary arteries via an endothelial-dependent vasodilator mechanism.
This result is concordant with other evidence suggestive of a beneﬁcial
effect of RIPC on peripheral endothelial function [23]. In animal models,
ischaemic preconditioning prevents endothelial dysfunction following
ischaemia-reperfusion injury [46]. In 30 patients undergoing invasive
management of stable CAD, Lanza et al. demonstrated that invasive cor-
onary angiography was associated with an impairment of peripheral
endothelial function, and that RIPC prevented this detrimental effect
[31]. For theﬁrst time,we extend this observation to the coronary circu-
lation. Hoole et al. demonstrated in 242 patients with stable CAD under-
going elective PCI, a lower peri-procedural cardiac troponin release and
reduced major adverse cardiac events at 6 months and 6 years follow-
up [8,47]. It is plausible that less coronary vasoconstriction, secondary
to enhanced endothelial function induced by the RIPC stimulus, may
result in better maintenance of myocardial perfusion (i.e. reduced
ischaemia) and therefore less ischaemic injury in the heart. However,
we did not demonstrate a between-group difference in ST-segment
deviation during endothelial function testing. It is plausible that the
serial ECGs lacked sensitivity for changes in myocardial perfusion
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the ischaemic cascade, such as stress perfusion cardiac magnetic reso-
nance imaging, may have detected changes in myocardial perfusion.
In general, RIPC has been associated with reduced infarct size in
proof-of-concept clinical studies [8–11,17]. It is plausible that one
mechanism by which RIPC acts to reduce infarct size is to modify
functional microvascular obstruction by altering the balance between
pathological vasoconstriction and vasodilation and thus increasing
myocardial blood ﬂow [48]. Whether the attenuation in infarct size is
sufﬁcient to translate to improved clinical outcomes in patients follow-
ing acute MI is currently being assessed in the CONDI-2 and ERIC phase
3 clinical trials. These pivotal trials are currently enrolling and are sufﬁ-
ciently large (overall sample size N4000 patients) to provide conclusive
results on the potential clinical beneﬁts of RIPC in STEMI. In other set-
tings, such as surgical revascularisation, RIPC has not been associated
with improved health outcomes [49–51].
Experimental studies suggest that the mechanism of RIPC is similar
to that of ischaemic preconditioning and the mechanistic pathway
which conveys the cardioprotective signal is likely to involve both neu-
ral and humeral responses [21,23]. We did not identify a circulating
humoral factor derived from the vascular endothelium that may have
mediated the favourable effects of RIPC on coronary artery function.
There were no between-group differences in R-R interval, implying
that a neural mechanism may not mediate the coronary vasoactive
effects of RIPC. Further studies are warranted to assess the role of the
sympathetic nervous system in RIPC.
Ischaemic preconditioning was ﬁrst described in 1986 [1], and has
been investigated in acute STEMI (type 1 MI), elective PCI (to reduce
type 4a MI), and surgical coronary revascularisation (to reduce type 5
MI) [52]. Our randomised, controlled trial has identiﬁed RIPC-
mediated effects on coronary artery function as a potential mechanism
thatmay contribute to RIPC cardioprotection. Themechanisms involved
in RIPC are the subject of intense research (e.g. the Consortium for pre-
clinicAl assESsment of cARdioprotective therapies (CAESAR) [53].
Whether the favourable effect of RIPC on coronary artery function
might translate into patient beneﬁts, such as improved prognosis
following acute MI, will be explored in current trials.
5. Limitations
Although patients were not blinded to their treatment group assign-
ment, the primary and secondary outcomes were independent of any
subjective responses from the participants. We undertook coronary re-
activity testing in a single coronary artery, selected based on feasibility
for instrumentation and epicardial disease characteristics. Although
the sample size is limited, our studywas prospectively designed and ad-
equately powered to assess for between-groupdifferences in the prima-
ry outcome. The statistical analysis was performed by a biostatistician
independent of the research group. The statistical analysis with
ANCOVA was adopted to allow for variations in endothelial function
that might be related to between-patient differences in the extent and
nature of vascular risk factors [36].
There was a statistically signiﬁcant difference in the resting diastolic
blood pressure (70.4 vs. 75.9 mm Hg in the sham and RIPC groups re-
spectively), however there was no difference in systolic blood pressure
or in the between-group distribution of a history of arterial hyperten-
sion. There was a statistically signiﬁcant difference in the number
of patients taking regular β-blocker therapy at baseline (29 versus
22 patients in the shamandRIPC groups respectively).β-blocker therapy
may itself be cardioprotective, may attenuate the cardioprotective effect
of RIPC [54], and may enhance endothelial function. Therefore, it may
be hypothesised that we may have observed an even greater extent of
enhanced coronary endothelial function had there been no between-
group difference in β-blocker therapy at baseline.
We assessed coronary vasoreactivity with intracoronary acetylcho-
line and QCA as ﬁrst described by Ludmer et al. in 1986 [40]. Thistechnique allows assessment of coronary epicardial and microvascular
endothelial-dependent and -independent vasodilation [39]. In contrast,
simultaneous coronary blood ﬂow assessmentwould have required use
of an intracoronary Doppler guidewire. In order tominimise instrumen-
tation of normal or minimally-diseased coronary arteries, and in the in-
terests of patient safety, we did not use this method. Invasive indices of
coronary microvascular resistance and vasodilatory capacity were not
measured since prior studies have found that RIPC did not affect coro-
nary resistance [43]. In this regard, QCA of the mean coronary artery
lumen diameter is a reliable and sensitive parameter.
We did not collect coronary venous blood since additional instru-
mentation with right heart catheterisation may lead to patient discom-
fort and risk. Nor didwe use pharmacological agents, such as endothelin
or a nitric oxide synthase inhibitor, which could provoke sustained va-
soconstriction. There were no SAEs related to the coronary reactivity
testing in this study.
We did not assess cardiac biomarkers as this was a mechanistic
study, and the effect of RIPC on surrogate cardiac outcomes e.g. troponin
post-PCI, has already been described [8]. For logistical reasons we did
not record heart rate variability, which may have provided further
insights into autonomic nervous system activation.
6. Conclusions
Wehave performed a randomised, sham-controlled, single-blind clin-
ical trial that for theﬁrst timeprovides a fundamental new insight into the
mechanisms by which RIPC may have meaningful cardioprotective
effects; namely by enhancing coronary artery endothelial function in
patients with stable CAD.
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